Published in J Exp Med on December 01, 1984
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J Exp Med (1988) 2.42
Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun (1987) 2.09
Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun (1988) 1.97
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
Role of lipopolysaccharide in opsonization and phagocytosis of Pseudomonas aeruginosa. Infect Immun (1985) 1.54
Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus. J Biol Chem (2008) 1.42
Molecular basis for serum resistance in Neisseria gonorrhoeae. Clin Microbiol Rev (1989) 1.32
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest (1989) 1.25
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 1.23
Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun (1986) 1.20
Meningococcal disease and the complement system. Virulence (2013) 1.19
Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun (2003) 1.18
IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111. J Exp Med (1985) 1.11
Analysis of C3 deposition and degradation on Neisseria meningitidis and Neisseria gonorrhoeae. Infect Immun (1994) 1.04
Capsular polysaccharide regulates neutrophil complement receptor interactions with type III group B streptococci. Infect Immun (1993) 0.98
Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest (1995) 0.96
Complement regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein (CRP). Clin Exp Immunol (1998) 0.96
Structure-function analysis of the C3 binding region of Staphylococcus aureus immune subversion protein Sbi. J Biol Chem (2008) 0.96
C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway. Biochem J (1989) 0.91
Mechanism of complement-dependent haemolysis via the lectin pathway: role of the complement regulatory proteins. Clin Exp Immunol (1999) 0.89
Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem J (2000) 0.88
Naturally occurring anti-band 3 antibodies have a unique affinity for C3. Immunology (1993) 0.87
Enhancement of lectin pathway haemolysis by immunoglobulins. Clin Exp Immunol (1999) 0.86
Influence of serotype of group B streptococci on C3 degradation. Infect Immun (1992) 0.85
Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement. Immunology (1987) 0.81
Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein. MBio (2015) 0.80
Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes. Clin Exp Immunol (1998) 0.79
C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study. Clin Exp Immunol (1988) 0.78
Interactions of monomeric IgG bearing covalently bound C3b with polymorphonuclear leucocytes. Immunology (1987) 0.75
Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology (2016) 0.75
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med (1980) 3.48
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J (1981) 1.95
Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc Natl Acad Sci U S A (1981) 1.82
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan. J Immunol (1981) 1.57
Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J Immunol (1978) 1.54
Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46
Complement receptors. Clin Immunol Rev (1983) 1.37
Low ionic strength or chemical cross-linking of monomeric C3b increases its binding affinity to the human complement C3b receptor. Immunology (1983) 1.35
Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun (1983) 1.31
The binding of activated C3 to polysaccharides and immunoglobulins. J Immunol (1978) 1.29
Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates. J Immunol (1984) 1.20
Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system. J Immunol (1984) 1.14
Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. J Immunol (1983) 1.12
IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J Immunol (1981) 1.10
Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J Immunol (1982) 1.04
Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells. J Immunol (1983) 1.02
Generation of low m.w., C3-bearing immunoglobulin in human serum. J Immunol (1983) 1.01
Interaction of C3 and C3b with immunoglobulin G. Mol Immunol (1983) 0.95
Large scale isolation of functionally active components of the human complement system. J Biol Chem (1981) 5.26
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med (1996) 3.89
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Receptors for complement and immunoglobulin on human leukemic cells and human lymphoblastoid cell lines. J Clin Invest (1972) 3.64
The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol (1974) 3.38
Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med (1976) 3.10
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med (1976) 2.96
Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88
Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J Clin Invest (1972) 2.82
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol (1974) 2.60
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol (1992) 2.50
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Bactericidal and opsonic properties of C4-deficient guinea pig serum. J Immunol (1972) 2.48
A receptor for the third component of complement in the human renal glomerulus. J Exp Med (1975) 2.39
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet (1981) 2.29
In vitro studies of complement function in sera of C4-deficient guinea pigs. J Exp Med (1971) 2.29
Expression of specific binding sites on Candida with functional and antigenic characteristics of human complement receptors. J Immunol (1986) 2.28
Nodular lymphoma--evidence for origin from follicular B lymphocytes. N Engl J Med (1974) 2.26
Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: studies in patients with dermatitis herpetiformis and normal subjects. N Engl J Med (1981) 2.19
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15
The effect of temperature on the reactivity of guinea-pig complement with gamma G and gamma M haemolytic antibodies. Immunology (1970) 2.14
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. J Immunol (1986) 2.09
Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature. Medicine (Baltimore) (1977) 2.07
The localization of non-microbial antigens in the draining lymph nodes of tolerant, normal and primed rabbits. Immunology (1967) 2.07
Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet (1991) 2.05
The role of complement in inflammation and phagocytosis. Immunol Today (1991) 2.04
Ontogeny of B lymphocytes. II. Relative rates of appearance of lymphocytes bearing surface immunoglobulin and complement receptors. J Exp Med (1974) 2.03
Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A (1981) 2.02
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
In vivo studies in C4-deficient guinea pigs. J Exp Med (1971) 2.00
Complement and bacteria: chemistry and biology in host defense. Annu Rev Immunol (1984) 1.87
The critical role of complement in experimental pneumococcal sepsis. J Infect Dis (1980) 1.87
Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest (1972) 1.82
Complement depletion in cryptococcal sepsis. J Immunol (1978) 1.82
The complement system in host defense and inflammation. Rev Infect Dis (1980) 1.80
NIH Conference: Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med (1983) 1.79
A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. Proc Natl Acad Sci U S A (1973) 1.74
Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol (1974) 1.73
Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med (1972) 1.73
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
Increased ion permeability of planar lipid bilayer membranes after treatment with the C5b-9 cytolytic attack mechanism of complement. Proc Natl Acad Sci U S A (1976) 1.69
C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med (1988) 1.67
Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med (1981) 1.65
Hereditary deficiency of the sixth component of complement in man. I. Immunochemical, biologic, and family studies. J Clin Invest (1974) 1.65
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis (1983) 1.63
Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption. Mol Microbiol (1993) 1.63
The subunits in rabbit anti-Forssman IgM antibody. J Exp Med (1968) 1.60
A simple method for the determination of complement receptor-bearing mononuclear cells. J Immunol (1976) 1.59
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
The effect of Bacillus Calmette-Guerin-induced macrophage activation on the in vivo clearance of sensitized erythrocytes. J Clin Invest (1974) 1.58
Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications. J Clin Invest (1979) 1.58
Acquired C1 esterase inhibitor deficiency and angioedema: a review. Medicine (Baltimore) (1979) 1.57
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
On the mechanism of cytolysis by complement: evidence on insertion of C5b and C7 subunits of the C5b,6,7 complex into phospholipid bilayers of erythrocyte membranes. Proc Natl Acad Sci U S A (1975) 1.57
Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest (1974) 1.54
Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J Immunol (1987) 1.51
Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis (1992) 1.49
Studies on the fibronectin receptors of human peripheral blood leukocytes. Morphologic and functional characterization. J Exp Med (1984) 1.48
Evidence that rabbit gamma G haemolysin in capable of utilizing guinea-pig complement more efficiently than rabbit gamma M haemolysin. Immunology (1970) 1.48
Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46
Role of complement in host defense against experimental disseminated candidiasis. J Infect Dis (1978) 1.46
Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest (1978) 1.45
Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med (1987) 1.44
Mechanism of bacterial resistance to complement-mediated killing: inserted C5b-9 correlates with killing for Escherichia coli O111B4 varying in O-antigen capsule and O-polysaccharide coverage of lipid A core oligosaccharide. Infect Immun (1984) 1.42
On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes. J Immunol (1977) 1.41
C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma. J Immunol (1987) 1.41
The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest (1976) 1.40
Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children. J Infect Dis (1990) 1.40
The role of late complement components and the alternate complement pathway in experimental cryptococcosis. Proc Soc Exp Biol Med (1973) 1.38
The glomerular complement receptor in immunologically mediated renal glomerular injury. N Engl J Med (1976) 1.38
C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol (1996) 1.37
Leukemic reticuloendotheliosis: presence of a receptor for cytophilic antibody. Am J Med (1974) 1.37
The fourth component of complement in the cerebrospinal fluid in systemic Lupus erythematosus. Arthritis Rheum (1973) 1.37